Laurie McLay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laurie McLay has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Karyn G. France
Te Kaupeka Oranga, Faculty of Health, University of Canterbury, Christchurch, New Zealand
12 shared publications - Neville M. Blampied
University of Canterbury, Christchurch, New Zealand
11 shared publications - Emma C. Woodford
University of Canterbury, Ilam, Christchurch, New Zealand
7 shared publications - Nicholas Bowden
University of Otago, Dunedin, New Zealand
6 shared publications - Philip J. Schluter
Faculty of Health, University of Canterbury, Christchurch, New Zealand
6 shared publications - Jenna van Deurs
Te Kaupeka Oranga | Faculty of Health, Te Whare Wānanga o Waitaha | University of Canterbury, Christchurch, New Zealand
5 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by SAGE Publications in Autism
- Vol. 30 (8) , 2151-2159
Intersections of Autism and Sexual and Gender Diversity Among Young People in New Zealand
International research suggests there is a common intersection between Autism and sexual and gender diversity. However, there is limited data estimating the whole-of-population prevalence of this association, both abroad and in Aotearoa New Zealand (NZ). Utilising NZ’s Integrated Data Infrastructure, a research database containing linked administrative and survey data, we conducted a nationwide cohort study of those in the age range 5–24 years for whom Census 2023 records existed. From a study population of 1,266,453 young people, 1.5% were identified as Autistic. After adjustment for demographic measures, we found significantly higher rates of Autism among sexually- and gender-diverse young people than among their heterosexual and cisgender peers. This included for those identifying with a gender outside of the male/female binary (3.9%) compared to both males (2.3%; 1.7 times as high) and females (0.7%; 5.8 times as high), transgender people (4.0%) compared to cisgender people (1.5%; 2.9 times as high), and non-heterosexuals (2.2%) compared to heterosexuals (1.4%; 1.8 times as high). Lay International research suggests there is a common overlap between Autism and sexual and gender diversity (such as people who are gay, lesbian, transgender, etc). However, there is little data about this association on a whole-of-population scale. We conducted a nationwide study of young people aged 5–24 years to explore this crossover. From a study population of 1,266,453 young people, 1.5% were identified as Autistic. Looking at sexual- and gender-diversity data, we found there were significantly higher proportion of people who were Autistic among sexually and gender-diverse young people compared to their heterosexual and cisgender peers.
- 8 July 2026
- Published by SAGE Publications in Autism
- Vol. 30 (8) , 2151-2159
Open AccessIntersections of Autism and Sexual and Gender Diversity Among Young People in New Zealand
International research suggests there is a common intersection between Autism and sexual and gender diversity. However, there is limited data estimating the whole-of-population prevalence of this association, both abroad and in Aotearoa New Zealand (NZ). Utilising NZ’s Integrated Data Infrastructure, a research database containing linked administrative and survey data, we conducted a nationwide cohort study of those in the age range 5–24 years for whom Census 2023 records existed. From a study population of 1,266,453 young people, 1.5% were identified as Autistic. After adjustment for demographic measures, we found significantly higher rates of Autism among sexually- and gender-diverse young people than among their heterosexual and cisgender peers. This included for those identifying with a gender outside of the male/female binary (3.9%) compared to both males (2.3%; 1.7 times as high) and females (0.7%; 5.8 times as high), transgender people (4.0%) compared to cisgender people (1.5%; 2.9 times as high), and non-heterosexuals (2.2%) compared to heterosexuals (1.4%; 1.8 times as high). Lay International research suggests there is a common overlap between Autism and sexual and gender diversity (such as people who are gay, lesbian, transgender, etc). However, there is little data about this association on a whole-of-population scale. We conducted a nationwide study of young people aged 5–24 years to explore this crossover. From a study population of 1,266,453 young people, 1.5% were identified as Autistic. Looking at sexual- and gender-diversity data, we found there were significantly higher proportion of people who were Autistic among sexually and gender-diverse young people compared to their heterosexual and cisgender peers.
- Open Access
- 6 July 2026
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- p. 1-16
The Effect of Participation in the Let’s Play Program on Autistic Children’s Engagement and Caregiver Well-Being: A Randomized Controlled Trial
Purpose: In Aotearoa New Zealand (NZ), families face persistent barriers to accessing evidence-based early support for Autistic children. This randomized controlled trial (RCT) evaluated the effectiveness of Let’s Play; a bespoke, caregiver-mediated early support program for Autistic children and their caregivers. Methods: This single-blind (rater) RCT included 91 parent-child dyads, randomly assigned to the Let’s Play program (active support; AS [ n = 45]) or a waitlist control (WLC; n = 46). Participants were caregivers of children aged 0 to 5 years with a formal diagnosis or characteristics of autism. Let’s Play was delivered over 9 weeks via group workshops and in-home coaching. Primary child and caregiver outcomes, assessed at baseline, post-support, and 6-month follow-up, included parent-child engagement and parental stress, respectively. Results: Children showed descriptive evidence of improvement in caregiver-child engagement, health-related quality of life and behaviour from baseline to post-support. Improvement in parental stress, depression and anxiety symptoms, and self-perceived parenting competence were also evident, across timepoints. However, there were no significant Group x Ttime effects for caregiver-child engagement, number of utterances or number of different words. A Group x Time effect was evident for all other child and caregiver outcome variables, underscoring the benefits of Let’s Play. Conclusions: This research provides preliminary evidence of the effectiveness of a low-intensity, community-based, caregiver-mediated early support program for Autistic children’s health-related quality of life and behavior and caregiver well-being. However, more targeted or sustained approaches to supporting caregiver-child engagement and vocal communication may be needed for improvement to be observed. Clinical Trial Registration: The research protocol was prospectively registered on the Australian New Zealand Clinical Trials Registry (ACTRN12622001139763).
- 6 July 2026
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- p. 1-16
Open AccessThe Effect of Participation in the Let’s Play Program on Autistic Children’s Engagement and Caregiver Well-Being: A Randomized Controlled Trial
Purpose: In Aotearoa New Zealand (NZ), families face persistent barriers to accessing evidence-based early support for Autistic children. This randomized controlled trial (RCT) evaluated the effectiveness of Let’s Play; a bespoke, caregiver-mediated early support program for Autistic children and their caregivers. Methods: This single-blind (rater) RCT included 91 parent-child dyads, randomly assigned to the Let’s Play program (active support; AS [ n = 45]) or a waitlist control (WLC; n = 46). Participants were caregivers of children aged 0 to 5 years with a formal diagnosis or characteristics of autism. Let’s Play was delivered over 9 weeks via group workshops and in-home coaching. Primary child and caregiver outcomes, assessed at baseline, post-support, and 6-month follow-up, included parent-child engagement and parental stress, respectively. Results: Children showed descriptive evidence of improvement in caregiver-child engagement, health-related quality of life and behaviour from baseline to post-support. Improvement in parental stress, depression and anxiety symptoms, and self-perceived parenting competence were also evident, across timepoints. However, there were no significant Group x Ttime effects for caregiver-child engagement, number of utterances or number of different words. A Group x Time effect was evident for all other child and caregiver outcome variables, underscoring the benefits of Let’s Play. Conclusions: This research provides preliminary evidence of the effectiveness of a low-intensity, community-based, caregiver-mediated early support program for Autistic children’s health-related quality of life and behavior and caregiver well-being. However, more targeted or sustained approaches to supporting caregiver-child engagement and vocal communication may be needed for improvement to be observed. Clinical Trial Registration: The research protocol was prospectively registered on the Australian New Zealand Clinical Trials Registry (ACTRN12622001139763).
- 17 June 2026
- Published by Elsevier in Research in Neurodiversity
- Vol. 2
Prevalence, Understandings, and Experiences of Autism Among Pacific Peoples: A Scoping Review
- 17 June 2026
- Published by Elsevier in Research in Neurodiversity
- Vol. 2
Prevalence, Understandings, and Experiences of Autism Among Pacific Peoples: A Scoping Review
- Open Access
- 3 June 2026
- Published by Wiley in JCPP Advances
- p. e70133
Implications of attention‐deficit/hyperactivity disorder diagnostic timing on mental health service utilisation in young adult females: A population‐based record linkage cohort study
Background: Sex differences in the frequency and timing of attention‐deficit/hyperactivity disorder (ADHD) diagnosis exist. While there are multiple known individual and wider consequences for young females with delayed or undiagnosed ADHD, little is known about mental health service utilisation (HSU) impacts. Methods: A national population‐based cohort of females aged 18–24 years between July 1, 2021, to June 30, 2022, in Aotearoa New Zealand was established. ADHD‐index, intellectual disability (ID)‐index and age at index were derived using established algorithms. Four mental and two non‐mental health variables capturing HSU interactions between July 1, 2022, to June 30, 2024 were derived and analyzed for ADHD‐index participants. Unadjusted and adjusted modified Poisson regression models were utilised and reported. All analyses were stratified by ID‐index. Results: Overall, 212,385 females were included, of whom 5244 (2.5%) had ADHD‐index. Of those ADHD‐indexed, 486 were also ID‐indexed. For females ADHD‐indexed, 1638 (31.2%) were indexed at age < 12 years, 1575 (30.0%) at age 12–17 years, and 2031 (38.7%) at age 18–24 years. While different patterns emerged between females with and without ID, those with later ADHD diagnosis were associated with higher rates of psychotropic pharmaceutical dispensing, psychiatric inpatient stays, and non‐psychiatric hospitalisations compared to those with early diagnosis. For example, in the adjusted analysis comparing females without ID‐index who were ADHD‐indexed at age 12–17 years to their counterparts indexed at age < 12 years, the estimated incident rate ratio of psychiatric inpatient stay was 2.07 (95% CI 1.20–3.58). Conclusion: Later ADHD diagnosis among a national cohort of young adult females was common. A later diagnosis was associated with increased mental and non‐mental HSU compared to those with earlier diagnosis. Earlier detection of ADHD in females may mitigate their personal burden and reduce subsequent service use.
- 3 June 2026
- Published by Wiley in JCPP Advances
- p. e70133
Open AccessImplications of attention‐deficit/hyperactivity disorder diagnostic timing on mental health service utilisation in young adult females: A population‐based record linkage cohort study
Background: Sex differences in the frequency and timing of attention‐deficit/hyperactivity disorder (ADHD) diagnosis exist. While there are multiple known individual and wider consequences for young females with delayed or undiagnosed ADHD, little is known about mental health service utilisation (HSU) impacts. Methods: A national population‐based cohort of females aged 18–24 years between July 1, 2021, to June 30, 2022, in Aotearoa New Zealand was established. ADHD‐index, intellectual disability (ID)‐index and age at index were derived using established algorithms. Four mental and two non‐mental health variables capturing HSU interactions between July 1, 2022, to June 30, 2024 were derived and analyzed for ADHD‐index participants. Unadjusted and adjusted modified Poisson regression models were utilised and reported. All analyses were stratified by ID‐index. Results: Overall, 212,385 females were included, of whom 5244 (2.5%) had ADHD‐index. Of those ADHD‐indexed, 486 were also ID‐indexed. For females ADHD‐indexed, 1638 (31.2%) were indexed at age < 12 years, 1575 (30.0%) at age 12–17 years, and 2031 (38.7%) at age 18–24 years. While different patterns emerged between females with and without ID, those with later ADHD diagnosis were associated with higher rates of psychotropic pharmaceutical dispensing, psychiatric inpatient stays, and non‐psychiatric hospitalisations compared to those with early diagnosis. For example, in the adjusted analysis comparing females without ID‐index who were ADHD‐indexed at age 12–17 years to their counterparts indexed at age < 12 years, the estimated incident rate ratio of psychiatric inpatient stay was 2.07 (95% CI 1.20–3.58). Conclusion: Later ADHD diagnosis among a national cohort of young adult females was common. A later diagnosis was associated with increased mental and non‐mental HSU compared to those with earlier diagnosis. Earlier detection of ADHD in females may mitigate their personal burden and reduce subsequent service use.
- Open Access
- 23 April 2026
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 18 (1)
Prevalence and age of diagnosis of neurodevelopmental conditions among Asian populations in Aotearoa New Zealand
Purpose: Asian populations are among the fastest-growing ethnic groups in Aotearoa New Zealand (NZ), yet little is known about the prevalence of neurodevelopmental conditions (NDCs) within these communities. The study compared the prevalence and age of diagnosis of NDCs (Attention Deficit Hyperactivity Disorder [ADHD], autism, communication and language disabilities [CLDs], intellectual disability [ID], motor disabilities [MDs], and specific learning disabilities [SLDs]) between NZ-born Asian and non-Asian populations, and differences across Asian subgroups. Methods: A national cross-sectional analysis was conducted using linked administrative microdata from the Integrated Data Infrastructure, covering the 2021/22 estimated resident population aged 0–24 years ( N = 1,334,247). Following adjustment for socioeconomic factors, standardized NDC rates were calculated for Asian and non-Asian populations and Asian subgroups (Indian, Chinese, Southeast Asian, and Other Asian). Results: Lower standardized rates of NDCs were identified among Asian (2.85%, 95% CI [2.77, 2.94]) compared to non-Asian (4.52%, 95% CI [4.49, 4.56]) participants. Most notably, rates of ADHD (1.1%, 95% CI [1.05, 1.16] vs. 2.94%, 95% CI [2.91, 2.97]) and ID (0.34%, 95% CI [0.31, 0.38] vs. 0.58%, 95% CI [0.57, 0.60]) were significantly lower among Asian participants. Among Asian sub-groups, rates of NDCs were lowest for Chinese children, with particularly low rates of Autism, MDs and SLDs. Conclusion: Findings highlight substantial differences in NDC rates between NZ-born Asian and non-Asian ethnicities, suggesting that socioeconomic context, cultural perceptions, and diagnostic pathways may influence identification patterns across and between Asian subgroups. Culturally responsive approaches are critical for equitable NDC identification and support.
- 23 April 2026
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 18 (1)
Open AccessPrevalence and age of diagnosis of neurodevelopmental conditions among Asian populations in Aotearoa New Zealand
Purpose: Asian populations are among the fastest-growing ethnic groups in Aotearoa New Zealand (NZ), yet little is known about the prevalence of neurodevelopmental conditions (NDCs) within these communities. The study compared the prevalence and age of diagnosis of NDCs (Attention Deficit Hyperactivity Disorder [ADHD], autism, communication and language disabilities [CLDs], intellectual disability [ID], motor disabilities [MDs], and specific learning disabilities [SLDs]) between NZ-born Asian and non-Asian populations, and differences across Asian subgroups. Methods: A national cross-sectional analysis was conducted using linked administrative microdata from the Integrated Data Infrastructure, covering the 2021/22 estimated resident population aged 0–24 years ( N = 1,334,247). Following adjustment for socioeconomic factors, standardized NDC rates were calculated for Asian and non-Asian populations and Asian subgroups (Indian, Chinese, Southeast Asian, and Other Asian). Results: Lower standardized rates of NDCs were identified among Asian (2.85%, 95% CI [2.77, 2.94]) compared to non-Asian (4.52%, 95% CI [4.49, 4.56]) participants. Most notably, rates of ADHD (1.1%, 95% CI [1.05, 1.16] vs. 2.94%, 95% CI [2.91, 2.97]) and ID (0.34%, 95% CI [0.31, 0.38] vs. 0.58%, 95% CI [0.57, 0.60]) were significantly lower among Asian participants. Among Asian sub-groups, rates of NDCs were lowest for Chinese children, with particularly low rates of Autism, MDs and SLDs. Conclusion: Findings highlight substantial differences in NDC rates between NZ-born Asian and non-Asian ethnicities, suggesting that socioeconomic context, cultural perceptions, and diagnostic pathways may influence identification patterns across and between Asian subgroups. Culturally responsive approaches are critical for equitable NDC identification and support.
- Open Access
- 27 February 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Comparative efficacy and acceptability of sleep interventions for children and adolescents with autism spectrum disorders: a protocol for a systematic review and network meta-analysis
Background: Children and adolescents with autism spectrum disorder (ASD) frequently experience sleep problems. Although various pharmacological, behavioral, and physical interventions have demonstrated efficacy in improving sleep among children with ASD, the relative effectiveness of these interventions remains unclear. Methods: We will conduct a systematic literature search to identify randomized controlled trials that evaluate the efficacy of pharmacological (e.g., melatonin), psychological (e.g., cognitive behavioral therapy), and physical (e.g., bright light therapy) interventions for sleep problems in children with ASD. We will search PubMed, PsycINFO, Cochrane CENTRAL, major trial registries, and regulatory agency websites. We will assess the Cochrane Risk of Bias 2.0 (RoB 2.0) tool for primary outcome and the Risk Of Bias due to Missing Evidence in Network meta-analysis (ROB-MEN) tool for the bias due to missing network evidence. A network meta-analysis (NMA) will be performed to compare the included interventions. The primary outcome will be sleep onset latency, while secondary outcomes will include other sleep variables, all-cause dropouts, and sleep disturbances assessed using standardized measures. We will assess confidence in NMA(CINeMA). Discussion: Our NMA aims to provide evidence-based insights into the effectiveness of sleep interventions for clinicians, children with ASD, and their caregivers. This information will help guide treatment decisions and improve the quality of life for children with ASD and their families. Systematic review registration: PROSPERO CRD42024592795.
- 27 February 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Open AccessComparative efficacy and acceptability of sleep interventions for children and adolescents with autism spectrum disorders: a protocol for a systematic review and network meta-analysis
Background: Children and adolescents with autism spectrum disorder (ASD) frequently experience sleep problems. Although various pharmacological, behavioral, and physical interventions have demonstrated efficacy in improving sleep among children with ASD, the relative effectiveness of these interventions remains unclear. Methods: We will conduct a systematic literature search to identify randomized controlled trials that evaluate the efficacy of pharmacological (e.g., melatonin), psychological (e.g., cognitive behavioral therapy), and physical (e.g., bright light therapy) interventions for sleep problems in children with ASD. We will search PubMed, PsycINFO, Cochrane CENTRAL, major trial registries, and regulatory agency websites. We will assess the Cochrane Risk of Bias 2.0 (RoB 2.0) tool for primary outcome and the Risk Of Bias due to Missing Evidence in Network meta-analysis (ROB-MEN) tool for the bias due to missing network evidence. A network meta-analysis (NMA) will be performed to compare the included interventions. The primary outcome will be sleep onset latency, while secondary outcomes will include other sleep variables, all-cause dropouts, and sleep disturbances assessed using standardized measures. We will assess confidence in NMA(CINeMA). Discussion: Our NMA aims to provide evidence-based insights into the effectiveness of sleep interventions for clinicians, children with ASD, and their caregivers. This information will help guide treatment decisions and improve the quality of life for children with ASD and their families. Systematic review registration: PROSPERO CRD42024592795.
- Open Access
- 8 July 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e80023
Correction: Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial
[This corrects the article DOI: 10.2196/64360.].
- 8 July 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e80023
Open AccessCorrection: Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial
[This corrects the article DOI: 10.2196/64360.].
- Open Access
- 2 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Correction: Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- 2 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCorrection: Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
- Open Access
- 25 June 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e64360
Optimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial
Background: Even before the COVID-19 pandemic, caregivers of children with rare neurogenetic conditions (NGCs) experienced physical and mental health challenges. These challenges escalated during the COVID-19 pandemic due to crisis-level breakdowns in support services. Tele–mental health and parenting support services expanded rapidly in response to the COVID-19 pandemic and may be well suited to facilitate necessary support interventions for NGC caregivers. However, it remains unclear how to match these evidence-based interventions to individual NGC caregivers’ needs. Objective: Project WellCAST (Supporting Well-Being of Caregivers via Telehealth) is an early-phase clinical trial designed to prospectively test which evidence-based telehealth interventions best meet the needs of NGC caregivers. Methods: Interested and eligible NGC caregivers are enrolled in a 24-week program with 5 phases, including baseline (2 weeks), support program (12 weeks), and follow-up (2 weeks) periods; a 4-week gap separates the phases. Caregivers participate in 2 randomizations, namely support program assignment via a precision health algorithm versus quasi-random assignment and motivational coaching by another NGC caregiver and project staff member (“peer coaching”) versus standard check-ins by a staff member who is not an NGC caregiver (“staff coaching”). Virtual support programs include acceptance and commitment therapy, dialectical and behavioral therapy, culturally informed cognitive behavioral therapy, research units in behavioral intervention, naturalistic communication intervention, Durand sleep intervention, and self-guided resources. A subset of caregivers will participate as waitlist controls before engaging in support programs. We developed and optimized a personalized health decision tree algorithm that matches caregivers to telehealth support programs. We then proceeded to test the feasibility and efficacy of algorithm-assigned support programs across 4 waves of data collection, relative to quasi-random assignment and waitlist controls. During each wave, the personalized health algorithm relies on 2 weeks of baseline data collection using clinical tools and innovative smartphone-based ecological momentary assessments. Across waves, we also test the efficacy of a motivational peer-to-peer coaching protocol, deployed by trained NGC caregiver staff, in enhancing support program uptake and clinical outcomes. Results: Four waves of data collection are scheduled for August 2023 to September 2025. Preregistered analyses will contrast feasibility, efficacy, and acceptability across algorithms and coaching assignments. Multiple waves of data collection will allow us to continually optimize the algorithm and test incremental improvements across project phases. Secondary analyses will probe the feasibility and efficacy of individual evidence-based support programs and peer coaching. Conclusions: Project WellCAST will test whether a digital personalized health decision tree algorithm and peer coaching protocol can prospectively enhance telehealth support program outcomes among NGC caregivers. This project is relevant to the specific population of NGC caregivers and may also inform how brief digital assessments, precision health tools, and community-academic partnerships can enhance the public health response to mental health crises across other high-need populations. Trial Registration: ClinicalTrials.gov NCT05999448; https://clinicaltrials.gov/study/NCT05999448 and OSF Registries 10.17605/OSF.IO/8WNDP; https://osf.io/8wndp International Registered Report Identifier (IRRID): DERR1-10.2196/64360
- 25 June 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e64360
Open AccessOptimizing a Personalized Health Approach for Virtually Treating High-Risk Caregivers of Children With Neurogenetic Conditions (Project WellCAST): Protocol for a Randomized Controlled Trial
Background: Even before the COVID-19 pandemic, caregivers of children with rare neurogenetic conditions (NGCs) experienced physical and mental health challenges. These challenges escalated during the COVID-19 pandemic due to crisis-level breakdowns in support services. Tele–mental health and parenting support services expanded rapidly in response to the COVID-19 pandemic and may be well suited to facilitate necessary support interventions for NGC caregivers. However, it remains unclear how to match these evidence-based interventions to individual NGC caregivers’ needs. Objective: Project WellCAST (Supporting Well-Being of Caregivers via Telehealth) is an early-phase clinical trial designed to prospectively test which evidence-based telehealth interventions best meet the needs of NGC caregivers. Methods: Interested and eligible NGC caregivers are enrolled in a 24-week program with 5 phases, including baseline (2 weeks), support program (12 weeks), and follow-up (2 weeks) periods; a 4-week gap separates the phases. Caregivers participate in 2 randomizations, namely support program assignment via a precision health algorithm versus quasi-random assignment and motivational coaching by another NGC caregiver and project staff member (“peer coaching”) versus standard check-ins by a staff member who is not an NGC caregiver (“staff coaching”). Virtual support programs include acceptance and commitment therapy, dialectical and behavioral therapy, culturally informed cognitive behavioral therapy, research units in behavioral intervention, naturalistic communication intervention, Durand sleep intervention, and self-guided resources. A subset of caregivers will participate as waitlist controls before engaging in support programs. We developed and optimized a personalized health decision tree algorithm that matches caregivers to telehealth support programs. We then proceeded to test the feasibility and efficacy of algorithm-assigned support programs across 4 waves of data collection, relative to quasi-random assignment and waitlist controls. During each wave, the personalized health algorithm relies on 2 weeks of baseline data collection using clinical tools and innovative smartphone-based ecological momentary assessments. Across waves, we also test the efficacy of a motivational peer-to-peer coaching protocol, deployed by trained NGC caregiver staff, in enhancing support program uptake and clinical outcomes. Results: Four waves of data collection are scheduled for August 2023 to September 2025. Preregistered analyses will contrast feasibility, efficacy, and acceptability across algorithms and coaching assignments. Multiple waves of data collection will allow us to continually optimize the algorithm and test incremental improvements across project phases. Secondary analyses will probe the feasibility and efficacy of individual evidence-based support programs and peer coaching. Conclusions: Project WellCAST will test whether a digital personalized health decision tree algorithm and peer coaching protocol can prospectively enhance telehealth support program outcomes among NGC caregivers. This project is relevant to the specific population of NGC caregivers and may also inform how brief digital assessments, precision health tools, and community-academic partnerships can enhance the public health response to mental health crises across other high-need populations. Trial Registration: ClinicalTrials.gov NCT05999448; https://clinicaltrials.gov/study/NCT05999448 and OSF Registries 10.17605/OSF.IO/8WNDP; https://osf.io/8wndp International Registered Report Identifier (IRRID): DERR1-10.2196/64360
- Open Access
Outcomes of participating in the Let’s Play programme on 0–5-year-old autistic children’s engagement and caregivers’ stress: study protocol for a parallel randomised controlled trial
Introduction Vast empirical evidence highlights the importance of early identification, diagnosis and support for autistic children. Caregivers of autistic children often experience high levels of psychological distress; hence there is a need for parallel child and caregiver support. Autism New Zealand’s Let’s Play programme is a caregiver-mediated, community-based programme based on the principles of developmental and relational interventions (henceforth, developmental). Developmental interventions are evidence-based supports designed to enhance children’s learning within the context of developmentally appropriate, naturalistic settings (eg, everyday routines, play). We aim to evaluate the effects of the Let’s Play programme on autistic children’s engagement and caregiver stress. Methods and analysis This study will be a single-blind (rater) randomised controlled trial with two parallel arms: immediate programme access (intervention) versus a waitlist control. Participants will be 64 caregivers of children aged 0–5 years with diagnosed or suspected autism, allowing for 20% attrition, based on power calculations. The Let’s Play programme will be delivered over 9 weeks using a combination of small group workshops and in-home coaching. Primary outcome variables include child engagement and caregiver stress. Caregivers will complete measures at three time points (baseline, immediately post-programme and at the 6-month follow-up), and effectiveness will be analysed using generalised estimating equation models and intention-to-treat and per protocol analyses. Ethics and dissemination This trial was approved by Aotearoa New Zealand Ministry of Health’s Health and Disability Ethics Committee (2022 FULL 13041). Findings will be communicated nationally and internationally via conferences, journal publications and stakeholder groups (eg, service providers for autistic children). Results will be shared regardless of magnitude or direction of effect. Trial registration number ACTRN12622001139763.
Open AccessOutcomes of participating in the Let’s Play programme on 0–5-year-old autistic children’s engagement and caregivers’ stress: study protocol for a parallel randomised controlled trial
Introduction Vast empirical evidence highlights the importance of early identification, diagnosis and support for autistic children. Caregivers of autistic children often experience high levels of psychological distress; hence there is a need for parallel child and caregiver support. Autism New Zealand’s Let’s Play programme is a caregiver-mediated, community-based programme based on the principles of developmental and relational interventions (henceforth, developmental). Developmental interventions are evidence-based supports designed to enhance children’s learning within the context of developmentally appropriate, naturalistic settings (eg, everyday routines, play). We aim to evaluate the effects of the Let’s Play programme on autistic children’s engagement and caregiver stress. Methods and analysis This study will be a single-blind (rater) randomised controlled trial with two parallel arms: immediate programme access (intervention) versus a waitlist control. Participants will be 64 caregivers of children aged 0–5 years with diagnosed or suspected autism, allowing for 20% attrition, based on power calculations. The Let’s Play programme will be delivered over 9 weeks using a combination of small group workshops and in-home coaching. Primary outcome variables include child engagement and caregiver stress. Caregivers will complete measures at three time points (baseline, immediately post-programme and at the 6-month follow-up), and effectiveness will be analysed using generalised estimating equation models and intention-to-treat and per protocol analyses. Ethics and dissemination This trial was approved by Aotearoa New Zealand Ministry of Health’s Health and Disability Ethics Committee (2022 FULL 13041). Findings will be communicated nationally and internationally via conferences, journal publications and stakeholder groups (eg, service providers for autistic children). Results will be shared regardless of magnitude or direction of effect. Trial registration number ACTRN12622001139763.